GlobeNewswire - Stock Market News

Voxtur Announces Grant of Restricted Share Units and Stock Options

Sat, 06 Feb 2021 00:43 GMT

TORONTO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Voxtur Analytics Corp. (TSXV:VXTR) (“Voxtur” or “the Company”) today announced that, in accordance with the Restricted Share Unit Plan that was approved by the shareholders of Voxtur, previously iLOOKABOUT Corp., at its Special Meeting of Shareholders on January 22, 2021, the Company has granted a total of 7,250,000 Restricted Share Units to employees and a consultant which will vest 1/3 upon grant and 1/3 on each of the following two anniversaries of the grant date. A complete copy of the Restricted Share Unit Plan can be found as Exhibit A of the Company’s Management Information Circular dated December 21, 2020, a copy of which is available at www.sedar.com.

BIGG Digital Assets Inc. Announces Grant of Stock Options

Sat, 06 Feb 2021 00:29 GMT

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

Quantum Announces Adoption of A New Stock Option Plan

Sat, 06 Feb 2021 00:03 GMT

MONTREAL, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Quantum Numbers Corp. (“Quantum” or the “Corporation”) (TSX-V: QNC) is pleased to announce that it has adopted a new fixed number stock option plan (the “Plan”), for its directors, officers, employees and service providers, so as to attract, retain and motivate these individuals to continue in their collaboration and strive for the Corporation’s success. The Plan replaces and supersedes the Corporation’s previous fixed number stock option plan adopted on September 6, 2017.

Equillium Announces Closing of $30 Million Registered Direct Offering

Fri, 05 Feb 2021 22:36 GMT

LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit was $7.00, priced above the market under Nasdaq rules. The warrants have an exercise price of $14.00 per share, are immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15^th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.? ?

Pacific Biosciences Grants Equity Incentive Award to New Employee

Fri, 05 Feb 2021 22:00 GMT

MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “2020 Inducement Plan”).

Emerita Resources Grants Options

Fri, 05 Feb 2021 21:24 GMT

TORONTO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTC: EMOTF) (the “Company” or “Emerita”) has granted a total of 3,900,000 stock options to various directors and officers pursuant to its stock option plan. The options may be exercised at a price of $0.18 per option for a period of five years from the date of grant. The grant of options remains subject to the approval of the TSX Venture Exchange.

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 05 Feb 2021 21:05 GMT

DUBLIN, Ireland, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and?neurodegenerative diseases, today announced that in connection with hiring three new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 75,000 ordinary shares of the Company. The options have an exercise price per share equal to $11.00, which was the closing trading price on February 1, 2021, the date of the grants. The inducement awards will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the date of grants and 1/48th of the underlying shares vesting monthly thereafter over 36 months. The options were granted pursuant to the Company’s 2020 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

SeaSpine Reports Granting of Inducement Awards

Fri, 05 Feb 2021 21:05 GMT

CARLSBAD, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has issued inducement awards to nine non-executive employees.

Pender Growth Fund Provides Notice of its Intention to Undertake Normal Course Issuer Bid

Fri, 05 Feb 2021 21:04 GMT

VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- (TSXV: PTF) Pender Growth Fund Inc. (the “Company”) announces that it has provided the TSX Venture Exchange (the "TSXV") with its Notice of Intention to make a Normal Course Issuer Bid (the "NCIB") through the facilities of the TSXV, subject to TSXV acceptance.

Allied Announces Pricing of $600 Million Green Bond Offering

Fri, 05 Feb 2021 19:55 GMT

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

Bespoke Capital Acquisition Corp. Announces Listing on Nasdaq

Fri, 05 Feb 2021 19:44 GMT

TORONTO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bespoke Capital Acquisition Corp. (NASDAQ: BSPE) (TSX: BC.U) (TSX: BC.WT.U) (OTCPK:BKCQ.F) (“Bespoke” or “BCAC”), a publicly-traded special purpose acquisition company, announced today that its Class A Restricted Voting shares were approved for listing on the Nasdaq Global Market, and will begin trading on the Nasdaq on Monday, February 8, 2021 under the symbol “BSPE”. Bespoke’s Warrants will continue to trade OTC in the U.S. Bespoke’s Class A Shares and warrants will remain listed on the Toronto Stock Exchange under its current symbols.

Exco Technologies Limited Announces Normal Course Issuer Bid

Fri, 05 Feb 2021 18:59 GMT

TORONTO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Exco Technologies Limited (TSX: XTC) ("Exco" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has approved the Company's normal course issuer bid ("NCIB"). Under the NCIB, Exco has the right to purchase for cancellation, from February 18, 2021 to February 17, 2022, a maximum of 1,960,000 common shares, representing 9.5% of the 20,575,656 shares forming Exco's public float as at February 3, 2021. As of February 5, 2021, Exco had 39,268,997 common shares issued and outstanding.

CHAR Technologies Closes $6 Million Private Placement

Fri, 05 Feb 2021 18:53 GMT

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES?OR FOR DISSEMINATION IN THE UNITED STATES

Itamar Medical Announces Pricing of Public Offering of American Depositary Shares

Fri, 05 Feb 2021 14:44 GMT

CAESAREA, Israel, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the pricing of its public offering of 3,049,130 American Depositary Shares (“ADSs”) at a public offering price of $22.75 per ADS. The Company is selling 1,968,466 ADSs and one of its shareholders, Viola Growth 2 A.V. Limited Partnership (the “Selling Shareholder”), is selling 1,080,664 ADSs in the offering. Each ADS represents 30 ordinary shares of the Company. The gross proceeds to the Company from the offering are expected to be approximately $44.8 million and the gross proceeds to the Selling Shareholder from the offering are expected to be approximately $24.6 million, before deducting the underwriting discounts and commissions and other offering expenses payable by the Company. The Company and the Selling Shareholder have granted the underwriters a 30-day option to purchase up to an additional 457,369 ADSs in aggregate at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 9, 2021, subject to customary closing conditions.

Aton Announces Bridge Loan

Fri, 05 Feb 2021 14:35 GMT

VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Aton Resources Inc. (AAN: TSX-V) ("Aton" or the "Corporation") announces that it has entered into a bridge loan facility (the "Facility") with Ou Moonrider ("Moonrider"), a significant shareholder of the Corporation. Pursuant to the Facility, the Corporation may borrow up to C$400,000 from Moonrider, which Facility is repayable on the earlier of six months from closing, on the occurrence of various standard events of default, or on the closing of any debt or equity financing by the Corporation in an amount in excess of C$1.5 million. The Facility will bear interest at a rate of 12% per annum, payable when the Facility is due.

Osisko Development Closes Final Tranche of Non-Brokered Private Placement of Units

Fri, 05 Feb 2021 14:35 GMT

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Osisko Développement cl?ture la tranche finale du placement privé d’unités sans l’entremise d’un courtier

Fri, 05 Feb 2021 14:35 GMT

NE PAS DISTRIBUER AUX AGENCES DE TRANSMISSION DES éTATS-UNIS NI DIFFUSER AUX?éTATS-UNIS

BIGG Digital Assets Inc. Announces Closing of Over-Allotment Option

Fri, 05 Feb 2021 14:16 GMT

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

McEwen Mining Announces Fox Complex Growth Funding Secured by Registered Direct Offering

Fri, 05 Feb 2021 14:11 GMT

TORONTO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- McEwen Mining Inc. (the “Company” or “McEwen”) (NYSE and TSX: MUX), announces an oversubscribed registered direct offering with several existing and new institutional investors for the sale of an aggregate of 30,000,000 shares of common stock at a purchase price of $1.05 per share (the “Offering”).

Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

Fri, 05 Feb 2021 13:30 GMT

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million, before deducting the underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Angion. Angion has also granted the underwriters a 30-day option to purchase from Angion up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Angion’s common stock has been approved for listing on The Nasdaq Global Select Market and is expected to begin trading under the ticker symbol “ANGN” on February 5, 2021. The offering is expected to close on February 9, 2021, subject to satisfaction of customary closing conditions.